| Drug Name | ( Synjardy ( Empagliflozin / Metformin Hydrochlorid |
|---|---|
| Drug Class |
Anti-diabetic
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
Safety communication
|
| Specialty (Theraputic area) |
Endocrine
|
| Risk |
risk of diabetic ketoacidosis Risk of Rare but Serious Infection in the Genital Area with Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Risk of Fournier´s gangrene (necrotising fasciitis of the perineum) |
| safety communication |
|
| Dear Healthcare provider letter DHPC |
|